We hosted Shandong Weigao's CFO and IR team with investors on June 25 at our China Healthcare Corporate Day 2025. Bottom line: Mmgt noted 1) its full-year revenue growth guidance of 10–15% y/y remains unchanged. 1H25 may exhibit slower momentum, while management remains confident in a stronger 2H rebound due to a more favorable base (1H/2H24 revenue split at Rmb6.64bn/6.45bn) and accelerated new product contribution. 2) The ramp-up of new products is progressing as planned, particularly in perioperative car ...

24 June 2025 | 5:17PM EDT USA: Powell Reiterates That FOMC Is Well Positioned to Wait for Further Clarity Before Changing the Policy Stance BOTTOM LINE: In his prepared remarks before the House Financial Services Committee, Chair Powell reiterated that the FOMC was "well positioned to wait to learn more about the likely course of the economy before considering any adjustments to our policy stance." When asked whether the FOMC could cut rates in July, Powell noted that "he wouldn't want to point to a particu ...

25 June 2025 | 2:27AM HKT CATL (300750.SZ) Unlocking value through unit GP expansion; reinstate on A-share and initiate H-share at Buy | 300750.SZ | 12m Price Target: Rmb323.00 | Price: Rmb245.92 | Upside: 31.3% | | --- | --- | --- | --- | | 3750.HK | 12m Price Target: HK$343.00 | Price: HK$303.00 | Upside: 13.2% | 3. Robust earnings growth: We project a robust 25% EPS CAGR from 2024-2030E, driven by a combination of volume growth and unit GP expansion. Catalysts: 1) Positive quarterly earnings that indicat ...

Presenters: Sophia Dong - Investor Relations Director Bottom line: Management highlighted encouraging ex-China development progress of out-licensed assets including B7H3 ADC, B7H4 ADC and oral GLP-1. Product sales guidance of double-digit growth in 2025 was re-iterated, and key product Ameile targets peak sales of Rmb8bn with upsides from combination therapy. We expect potential deal-making opportunities to come from early-stage ADC (EGFR/cMET, CDH6, CDH17), KRAS G12Di and next-generation disease modifiers ...

24 June 2025 | 4:26PM HKT Genscript Biotech Corp. (1548.HK): China Healthcare Corporate Day 2025 — Expect steadily improving bottom line with ProBio recovering Presenters: Josie Zhou - Chief Financial Officer, Pengfei Duan - Investor Relations Director Bottom line: Mgmt highlighted: 1) ProBio bottoming out, upfront from LaNova deal booked, 2) protein to be the 2nd growth engine for life science group (LSG), and 3) expect steadily improving bottom line, share buybacks/dividends under consideration Key Takeaw ...

China Solar: Tracking profitability inflection May rush installation spike suggests deeper demand pullback into 2H25 Our China Solar Profitability Tracker follows monthly supply/demand and inventory dynamics by sub-sector, and the spot prices/input costs implied cash GP & EBITDA margin trends for companies under our coverage. Key highlights in June MTD: Sector view: We continue to expect capacity cuts in 2025E-26E (average 17% of end-24 capacity cut across main value chain) due to cash burn and market acces ...

24 June 2025 | 4:18PM EDT Americas Technology: Internet Analyzing the Impact of AI on Industry Profit Pools – Part I (Advertising Case Study) Introducing Our "AI Profit Pools" Series Since the launch of ChatGPT as a product in November of 2022, the primary debate among tech investors has been the scaling and performance of large language models and the competition that would ensue as infrastructure translated into changed computing behaviors. This debate (as most technology shifts have) manifested itself fi ...

Global Economics Comment: Assessing the Economic Impacts of the War in the Middle East (Briggs/Peters) 23 June 2025 | 9:33AM EDT Assessing the Economic Impacts of the War in the Middle East +1(212)902-0394 | jan.hatzius@gs.com Goldman Sachs & Co. LLC Joseph Briggs +1(212)902-2163 | joseph.briggs@gs.com Goldman Sachs & Co. LLC Sarah Dong +1(212)357-9741 | sarah.dong@gs.com Goldman Sachs & Co. LLC Megan Peters +44(20)7051-2058 | megan.l.peters@gs.com Goldman Sachs International c45a43530f604d12bcb9a82b5aa6b9f ...

Investment Rating - The report maintains a cautious outlook on China's real GDP growth due to demographic, debt, and de-risking challenges, while acknowledging potential upside risks from faster AI adoption [7][8]. Core Insights - China achieved a growth target of "around 5%" in 2024, primarily driven by exports and related manufacturing investments [5]. - The 2025 growth forecast is set at 4.6%, slightly above consensus, with inflation forecasts below consensus (CPI at 0.0% and PPI at -2.4%) [8][10]. - The report anticipates a widening fiscal deficit by 2.4 percentage points of GDP in 2025 compared to 2024, with total social financing stock growth expected to rise to 9.5% [8][10]. Summary by Sections Economic Growth Forecasts - The report outlines that China's GDP growth is projected at 4.6% for 2025, with domestic demand contributing 4.5% and consumption at 4.9% [10]. - Exports of goods are expected to decline by 2.4% in nominal USD terms, while imports are projected to decrease by 4.2% [10]. Inflation and Monetary Policy - CPI is forecasted to be 0.0% and PPI at -2.4% for 2025, indicating low inflationary pressures [8][10]. - The report suggests further cuts in the reserve requirement ratio (RRR) and policy rates in Q4 2025 [8]. Fiscal Policy and Government Debt - The augmented fiscal deficit is expected to reach 13.0% of GDP in 2025, reflecting increased government spending [10][60]. - China's total government debt is projected to be RMB166 trillion, which is 131% of GDP [69]. Trade and External Factors - Elevated US tariffs on Chinese goods are anticipated to negatively impact GDP growth, although exports to other countries may provide some offset [8]. - The report notes that the US effective tariff rate on China has dropped, which may reduce the drag on GDP growth [15]. Policy Measures - Ongoing and planned policy easing measures are expected to support technology and high-quality growth, with specific programs aimed at boosting consumption and investment [63].

24 June 2025 | 11:25PM HKT Giant Biogene Holding (2367.HK): Business Update: Containable impact from recent uncertainty; Reiterate FY25 guidance expecting Post recent uncertainty, Giant Biogene posted a follow up announcement on night of Jun 23 and hosted a virtual meeting to provide recent business update on Jun 24. Core message is reiterating FY25 full year guidance, i.e. sales/NI up 25-28%/21-24% yoy at RMB6.9-7.1bn/2.5-2.6bn (vs. GSe of RMB6.85bn/2.35bn) despite the ST disruption of 618 sales. The under ...